The Life Sciences team represented Esperion Therapeutics (NASDAQ: ESPR) in its announced licensing agreement with Daiichi Sankyo Europe (DSE) to provide DSE with exclusive rights to commercialize bempedoic acid and the bempedoic acid/ezetimibe combination pill in the European Economic Area and Switzerland. DSR will be responsible for commercialization in the territories.
Under the terms of the agreement, Esperion will receive an upfront cash payment of $150 million as well as $150 million upon first commercial sales in the territory. Esperion is also eligible to receive a substantial additional regulatory milestone payment upon the grant of the Marketing Authorization in the EU for the CV Risk Reduction Label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, Esperion is eligible to receive additional sales milestone payments as well as substantial tiered royalties on net territory sales.
Esperion is the Lipid Management Company passionately committed to developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated LDL-C.
For additional details on the agreement, please read the press release.